WallStSmart

Centene Corp (CNC)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Centene Corp generates 182% more annual revenue ($178.33B vs $63.32B). PFE leads profitability with a 11.8% profit margin vs -3.6%. CNC appears more attractively valued with a PEG of 1.25. CNC earns a higher WallStSmart Score of 57/100 (C).

CNC

Buy

57

out of 100

Grade: C

Growth: 7.3Profit: 3.5Value: 7.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.83

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 4.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CNCUndervalued (+85.0%)

Margin of Safety

+85.0%

Fair Value

$268.78

Current Price

$62.33

$206.45 discount

UndervaluedFair: $268.78Overvalued
PFEUndervalued (+13.8%)

Margin of Safety

+13.8%

Fair Value

$30.21

Current Price

$26.04

$4.17 discount

UndervaluedFair: $30.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CNC2 strengths · Avg: 9.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Free Cash FlowQuality
$3.40B8/10

Generating 3.4B in free cash flow

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$148.19B9/10

Large-cap with strong market position

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

CNC2 concerns · Avg: 1.5/10
Return on EquityProfitability
-30.1%2/10

ROE of -30.1% — below average capital efficiency

Profit MarginProfitability
-3.6%1/10

Currently unprofitable

PFE3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.704/10

Distress zone — elevated risk

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CNC

The strongest argument for CNC centers on Price/Book, Free Cash Flow. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : CNC

The primary concerns for CNC are Return on Equity, Profit Margin.

Bear Case : PFE

The primary concerns for PFE are Altman Z-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CNC profiles as a turnaround stock while PFE is a value play — different risk/reward profiles.

CNC carries more volatility with a beta of 1.09 — expect wider price swings.

PFE is growing revenue faster at 5.4% — sustainability is the question.

CNC generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

CNC scores higher overall (57/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Centene Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Centene Corporation is a large publicly traded company and a multi-line managed care enterprise that serves as a major intermediary for both government-sponsored and privately insured health care programs. It is a healthcare insurer that focuses on managed care for uninsured, underinsured, and low-income individuals.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?